-
公开(公告)号:US20200079770A1
公开(公告)日:2020-03-12
申请号:US16555432
申请日:2019-08-29
Applicant: Array BioPharma Inc.
Inventor: Ronald Jay Hinklin , Shelley Allen , Patrick Barbour , Adam Cook , Joshua Dahlke , John Gaudino , Ellen Laird , Oren T. McNulty , Qian Zhao
IPC: C07D471/04
Abstract: Provided herein are compounds of the Formula I: and stereoisomers, tautomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R9, X1 and G are as defined herein, which are inhibitors of one or more TAM kinases and/or c-Met kinase, and are useful in the treatment and prevention of diseases which can be treated with a TAM kinase inhibitor and/or a c-Met kinase inhibitor.
-
公开(公告)号:US10555944B2
公开(公告)日:2020-02-11
申请号:US16173100
申请日:2018-10-29
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: C07D401/02 , C07D401/10 , A61K31/437 , A61K31/4353 , A61K31/496 , C07D471/04 , A61P1/12 , A61P35/04 , C07D519/00 , A61P35/02 , A61P35/00 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K45/06 , A61K31/551
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US20190183886A1
公开(公告)日:2019-06-20
申请号:US16173100
申请日:2018-10-29
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: A61K31/496 , C07D471/04 , A61K31/551 , A61K31/4985 , A61P35/00 , A61K31/444 , A61K45/06 , A61P1/12 , A61K31/506 , A61K31/5377 , A61P35/02 , C07D519/00 , A61P35/04 , A61K31/4995
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US20180148445A1
公开(公告)日:2018-05-31
申请号:US15858929
申请日:2017-12-29
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , James Collier , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Ginelle A. Ramann , Tony P. Tang , Li Ren , Shane M. Walls
IPC: C07D471/04 , A61P35/00 , A61P1/00
CPC classification number: A61K31/4545 , A61K31/4162 , A61K31/444 , A61K31/497 , A61K31/501 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P1/00 , A61P1/12 , A61P35/00 , A61P35/02 , C07D471/04
Abstract: Provided herein are compounds of the Formula I: or pharmaceutically acceptable salt or solvate thereof, wherein A, B, X1, X2, X3, X4, Ring D, E, Ra, Rb, n and m have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
公开(公告)号:US20180134702A1
公开(公告)日:2018-05-17
申请号:US15858240
申请日:2017-12-29
Applicant: Array BioPharma, Inc.
Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
IPC: C07D471/04 , C07D519/00 , A61P35/04 , A61P1/12
CPC classification number: A61K31/496 , A61K31/444 , A61K31/4985 , A61K31/4995 , A61K31/506 , A61K31/5377 , A61K31/551 , A61K45/06 , A61P1/12 , A61P35/00 , A61P35/02 , A61P35/04 , C07D471/04 , C07D519/00
Abstract: Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
-
46.
公开(公告)号:US09096567B2
公开(公告)日:2015-08-04
申请号:US14231356
申请日:2014-03-31
Applicant: Array BioPharma Inc.
Inventor: Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff , Ganghyeok Kim
IPC: A61K31/352 , C07D311/04 , C07D311/58 , C07D405/12 , C07D407/12
CPC classification number: C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12
Abstract: Provided herein is a method of treating an allergic inflammatory disease selected from asthma, dermatitis, allergic rhinitis, urticaria, anaphylaxis, angioedemea, allergies, contact hypersensitivity, drug hypersensitivity, and allergic conjunctivitis in a mammal, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, to said mammal in need thereof, wherein A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 are as defined herein.
Abstract translation: 本文提供了一种治疗哺乳动物中选自哮喘,皮炎,过敏性鼻炎,荨麻疹,过敏反应,血管紧张素,过敏,接触超敏反应,药物过敏和过敏性结膜炎的过敏性炎性疾病的方法,其包括给予治疗有效量的化合物 其中A1,A2,W,L,G,R7a,R7b,R8,R9和R10如本文所定义。
-
47.
公开(公告)号:US20140221342A1
公开(公告)日:2014-08-07
申请号:US14231356
申请日:2014-03-31
Applicant: Array BioPharma Inc.
Inventor: Laurence E. Burgess , Christopher T. Clark , Adam Cook , Christopher P. Corrette , Robert Kirk DeLisle , George A. Doherty , Kevin W. Hunt , Todd T. Romoff , Ganghyeok Kim
IPC: C07D311/58 , C07D407/12 , C07D405/12
CPC classification number: C07D311/58 , C07D311/04 , C07D405/12 , C07D407/12
Abstract: Provided herein is a method of treating an allergic inflammatory disease selected from asthma, dermatitis, allergic rhinitis, urticaria, anaphylaxis, angioedemea, allergies, contact hypersensitivity, drug hypersensitivity, and allergic conjunctivitis in a mammal, comprising administering a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof, to said mammal in need thereof, wherein A1, A2, W, L, G, R7a, R7b, R8, R9 and R10 are as defined herein.
Abstract translation: 本文提供了一种治疗哺乳动物中选自哮喘,皮炎,过敏性鼻炎,荨麻疹,过敏反应,血管紧张素,过敏,接触超敏反应,药物过敏和过敏性结膜炎的过敏性炎性疾病的方法,包括给予治疗有效量的化合物 其中A1,A2,W,L,G,R7a,R7b,R8,R9和R10如本文所定义。
-
-
-
-
-
-